GlassScriptPhysician profile
Edward Brettholz
NPI 1093739393
$189,213.89
in general payments reported to CMS, 2019-2025
46 companies · $8,649 in 2025
The $8,649 reported for 2025 was more than what 92% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $81K · 2020: $14K · 2021: $29K · 2022: $32K · 2023: $6,087 · 2024: $20K · 2025: $8,649.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $18K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $7,233 · Food and Beverage: $5,202 · Travel and Lodging: $4,175.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $17,872.00 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $7,233.27 |
| Food and Beverage | $5,201.56 |
| Travel and Lodging | $4,174.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $58,770.26 | 2019 | |
| Napo Pharmaceuticals INC | $37,261.74 | 2019-2025 | Mytesi |
| Qol Medical, LLC | $27,167.88 | 2019-2024 | Sucraid, Sucraid |
| Phathom Pharmaceuticals, INC. | $19,330.72 | 2024-2025 | Voquezna |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $17,318.42 | 2019-2024 | Plenvu, Xifaxan |
| Takeda Pharmaceuticals U.S.A., INC. | $10,595.08 | 2019-2024 | Entyvio |
| Abbvie INC. | $6,680.62 | 2019-2024 | Skyrizi, Rinvoq, Linzess |
| Allergan, INC. | $5,855.09 | 2019 | |
| Celgene Corporation | $987.45 | 2019-2024 | Zeposia |
| Janssen Biotech, INC. | $883.10 | 2019-2023 | Stelara |
| Pfizer INC. | $675.69 | 2019-2025 | |
| Gilead Sciences, INC. | $456.07 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $390.19 | 2019-2024 | Dificid |
| Redhill Biopharma INC. | $309.43 | 2020-2022 | |
| Romark Laboratories, Lc | $254.41 | 2019-2020 |
Show all 46 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edward Brettholz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.